Grail
Preço: 59.85Empresa e modelo de negócios
Grail is a healthcare company focused on early cancer detection through advanced genomic testing. Its core products include multi-cancer early detection tests that analyze blood samples to identify various types of cancer at an early stage. The company primarily generates revenue from the sale of these diagnostic tests, targeting both healthcare providers and patients. Grail operates in the diagnostics segment of the healthcare industry, emphasizing innovation in cancer screening technologies.
Perfil de investimento
The investment profile of Grail suggests it may be more suitable for value investors due to its current financial challenges and lack of dividends. The stock's volatility and recent performance indicate a higher risk, which may not appeal to growth-focused investors. A balanced approach could be considered, but the overall outlook leans towards caution.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -10.37 Risco
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -6.4% ↓
- Surpresa de EPS
- 17.1% melhor que o esperado
- Volatilidade 20d
- 4.9% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:42 | Manter | Vender | scenario_deterioration |
| 2026-06-01 02:39 | Vender | Manter | Weak fundamentals and high volatility raise significant concerns. |
| 2026-05-08 15:27 | — | Vender | Weak fundamentals and high volatility raise significant concerns. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-05 06:33 | Goldman Sachs | Atualizar | — → 60 | 66.55 |
| 2026-05-06 11:22 | Piper Sandler | Preço-alvo elevado | 54 → 56 | 54.4 |
| 2026-05-06 10:47 | Robert W. Baird | Preço-alvo reduzido | 82 → 70 | 54.4 |
Nada ainda